Stable disease
The tumours have neither shrunk enough to count as a response nor grown enough to count as progression. For a slow cancer or a well-tolerated drug, months of stability can be a real benefit.
Under RECIST, stable disease is anything between a 30% decrease and a 20% increase in the sum of target-lesion diameters, with no new lesions. It is ambiguous on its own, because an indolent tumour may be stable without any treatment, so trials report the disease control rate (responses plus stable disease) with caution and prefer to measure how long disease stays controlled. Drugs that mainly stabilise rather than shrink, such as anti-angiogenics and some hormonal agents, are judged on progression-free and overall survival rather than response.
Pages like this
not linked directly; found by shared links- TermRemission
Shares Complete response, Partial response, Progression.
- TermDuration of response
Shares Complete response, Partial response, Progression-free survival (PFS).
- IdeaValidate real-world progression against central imaging review
Shares RECIST, Progression-free survival (PFS).
- IdeaMake clonal clearance, not tumour shrinkage, a trial endpoint
Shares RECIST, Progression-free survival (PFS).
- IdeaValidate real-world progression endpoints so pragmatic trials can use them
Shares RECIST, Progression-free survival (PFS).
- IdeaStructured, coded radiology reports for cancer response instead of free text
Shares RECIST, Progression-free survival (PFS).
- IdeaPublish the disagreement between trial doctors and independent reviewers for every trial
Shares RECIST, Progression-free survival (PFS).
- TermSurrogate endpoint